Management of tumor lysis syndrome: Need for evidence-based guidelines

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5657-5658

  Feusner, James H ^a   Ritchey, A Kim ^b   Cohn, Susan L ^c   Billett, Amy L ^d  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; RASBURICASE; VINCRISTINE;

ALKALINIZATION; BURKITT LYMPHOMA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERURICEMIA; LETTER; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; CHILD; DIURESIS; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE; MEDICAL ONCOLOGY; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RISK FACTORS; SALTS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 57149116172     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6030     Document Type: Letter

References (3)

1. Coiffier B, Altman A, Pui Ching-Hon, et al: Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 26:2767-2778, 2008
2. Goldman SC, Holcenberg JS, Finklestein JZ, et al: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998-3003, 2001
3. Conger JD, Falk SA: Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 59:786-793, 1977